Rockville biopharma’s ADHD drug emerges from the clinic with good news – Washington Business Journal

Related Articles:

• ADHD & PD: The Basal Ganglia and Cerebellum Connection January 22, 2019 Two parts within our brain require healthy dopamine regulation and transmission to do their jobs: The basal ganglia: messengers that sort out information for the spinal cord and cerebellum and are associated with various functions, including motor control, motor learning, executive functions and behaviors, and emotions. The cerebellum: involved in movement and coordination, walking, posture, reflexes, and eye and head…
• ADHD Diagnosis Could Increase Risk for Parkinson’s, Study Suggests September 14, 2018 People diagnosed with attention deficit/hyperactivity disorder (ADHD), usually detected at an early age in hyperactive children, may have an increased risk of developing Parkinson’s and Parkinson’s-like diseases, a new study suggests. “Parkinson’s disease is commonly thought of as a neurodegenerative disease associated with aging,” Glen Hanson, PhD, professor at the University of Utah Health and the study’s lead author, said in…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Family-based association study on functional α-synuclein polymorphisms in attention-deficit/hyperactivity disorder. March 31, 2019 Related ArticlesFamily-based association study on functional α-synuclein polymorphisms in attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord. 2019 Mar;11(1):107-111 Authors: Gerlach M, Sharma M, Romanos M, Lesch KP, Walitza S, Conzelmann HA, Krüger R, Renner TJ Abstract Studies have strongly suggested a disturbed regulation of dopaminergic neurotransmission in attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease (PD). A genetic and phenotypic overlap between both…
• NURR1 deficiency is associated to ADHD-like phenotypes in mice. August 29, 2019 Related ArticlesNURR1 deficiency is associated to ADHD-like phenotypes in mice. Transl Psychiatry. 2019 Aug 27;9(1):207 Authors: Montarolo F, Martire S, Perga S, Spadaro M, Brescia I, Allegra S, De Francia S, Bertolotto A Abstract The transcription factor NURR1 regulates the dopamine (DA) signaling pathway and exerts a critical role in the development of midbrain dopaminergic neurons (mDA). NURR1 alterations have…
• Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19 - WJLA April 7, 2020 Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19  WJLA
• Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19 - WJLA April 7, 2020 Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19  WJLA
• Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19 - WJLA April 7, 2020 Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19  WJLA
• Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19 - WJLA April 7, 2020 Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19  WJLA
• Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19 - WJLA April 7, 2020 Rockville boxing club reaches out to members battling Parkinson's disease amid COVID-19  WJLA
• The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
• The 2019 Linked Clinical Trials meeting October 16, 2019   Things were a bit quiet on the SoPD over the summer, but for good reasons. There was a short hiatus for a family break, but the rest of the time I was rather occupied with the day job. Tremendous efforts were being made at the Cure Parkinson’s Trust, as we were gearing up for our main event of the…
• I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center - PRNewswire April 8, 2019 I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center  PRNewswireBOSTON, April 7, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on the ...
• I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center - P&T Community April 8, 2019 I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center  P&T CommunityBOSTON, April 7, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on the ...
• I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center - BioSpace April 8, 2019 I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center  BioSpacePublished: Apr 08, 2019. BOSTON, April 7, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an ...
• GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies - BioSpace May 28, 2019 GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies  BioSpacePublished: May 28, 2019. GBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene ...
• Parkinson's Disease News - Editor's Picks (Archive 2016.07) September 30, 2016 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed Pedaling for Parkinson’sThat is what it’s like living with Parkinson’s disease. Parkinson’s disease is a chronic, neurodegenerative disorder in which the loss of cells in various parts of the brain leaves people less able to control their…
• GB Sciences Granted US Patent for Cannabinoid-based Formulations for Parkinson’s May 7, 2020 GB Sciences has been granted a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its proprietary cannabinoid-containing complex mixtures for treating Parkinson’s disease, the company announced. GB Sciences is creating a pipeline of new medicines based on cannabinoids, the pharmacologically active compounds that give the cannabis plant its medical and recreational properties. The patent — number 10,653,640…
• ADHD May Increase Parkinson’s Risk September 12, 2018 A new study reports those with ADHD are at an increased risk of developing Parkinson's disease. The study reveals people with ADHD are twice as likely to develop early onset Parkinson's between the ages of 21-66. Additionally, those who are prescribed stimulant medications to help reduce ADHD symptoms, including Ritalin and Adderal, are at a 6-8 times increased risk of…
• Center of Excellence Series: Rush University Medical Center Provides Critically Needed Parkinson’s Mental Health Program March 9, 2018 Most people associate Parkinson’s disease (PD) with tremors, a motor symptom. However, non-motor symptoms are common and can be more troublesome and disabling than motor symptoms. They can include cognitive changes, mood and sleep disorders, autonomic symptoms or weight loss. Rush University Medical Center, a Parkinson’s Foundation Center of Excellence, is not only on the front lines of PD-related cognitive…
• Psychosis Treatments October 28, 2019 Psychosis Treatments PSYCHOSIS TREATMENTS Generic Brand Form Indication Adult Initial Dose Adult Dose Titration First-Generation Antipsychotics chlorpromazine HCl — tabs Psychosis. Mania Less acutely disturbed: 25mg three times dailyOutpatient: 10mg 3–4 times daily or 25mg 2–3 times dailySevere cases: 25mg three times daily Inpatient: 500–1000mg/dayLess acutely disturbed: 400mg/dayOutpatient: 200–800mg/day Increase dose gradually until symptoms are controlled. Continue optimum dosage for…
• Real-World Data Links High-Blood Pressure Therapy With Parkinsonism, Researchers Report July 23, 2019 Propranolol, a beta-blocker therapy for high-blood pressure, may be associated with an increased risk of developing parkinsonism — any condition that causes a combination of the movement abnormalities seen in Parkinson’s disease, according to a large database study. Scientists also correlated five medications with a reduced risk of having Parkinson’s-like symptoms. These included medicines to promote wakefulness, and to treat…